Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

Rhea-AI Summary

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotech firm, will have its CEO, Kenneth A. Berlin, present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Berlin's presentation is scheduled for 2:30 PM ET on March 24. Interested investors can view the presentation and request meetings via registration at the conference's website. Advaxis specializes in immunotherapy products utilizing bioengineered Listeria monocytogenes for enhanced anti-tumor T-cell immunity. For more details, visit advaxis.com.

PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021. Mr. Berlin will present on March 24^th, 2021 at 2:30 pm ET.

Investors can view the presentation and request a 1x1 meeting once they register for the conference here.

Tune in to the YouTube link on Day 1 Track 1 at 2:30 pm ET for the presentation: https://www.youtube.com/watch?v=BOoOknbYO2c

About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com 
(212) 915-2564

FAQ

When will Advaxis (ADXS) present at the Benzinga Biotech Small Cap Conference?

Advaxis will present on March 24, 2021, at 2:30 PM ET.

How can investors view the Advaxis (ADXS) presentation?

Investors can view the presentation by registering for the Benzinga Biotech Small Cap Conference.

What technology does Advaxis (ADXS) use in its immunotherapy?

Advaxis utilizes bioengineered Listeria monocytogenes to develop its immunotherapy products.

What is the focus of Advaxis, Inc. (ADXS)?

Advaxis focuses on developing and commercializing proprietary Lm-based antigen delivery products for immunotherapy.